The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Ozempic is a brand-name version of semaglutide, an injectable glucagon-like peptide-1 (GLP-1) receptor agonist ... prescribed off-label for weight loss via brands like Ozempic.

Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...

Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...

GLP-1s have quickly ... potential of GLP-1 therapy. To achieve the best results, these programmes must focus on breaking down the common barriers that make weight loss so challenging, including ...

GLP-1s are approved to treat Type-2 diabetes, but are also effective as weight-loss drugs. But GLP-1 users may have to stay on them long-term to maintain their weight loss. Side effects and high ...